Dietary carbohydrates and fatty liver disease: de novo... : Current Opinion in Clinical Nutrition & Metabolic Care (original) (raw)

CARBOHYDRATES: Edited by Luc Tappy and Bettina Mittendorfer

de novo lipogenesis

aCollege of Osteopathic Medicine, Touro University California, Vallejo

bChildren's Hospital Oakland Research Institute, Oakland

cDepartment of Medicine, University of California, San Francisco

dDivision of Endocrinology, Zuckerberg San Francisco General Hospital, San Francisco, California, USA

Correspondence to Jean-Marc Schwarz, PhD, College of Osteopathic Medicine, Touro University California, 1310 Club Drive, Vallejo, CA 94592, USA. Tel: +1 707 638 5456; e-mail: [email protected]

Current Opinion in Clinical Nutrition and Metabolic Care 21(4):p 277-282, July 2018. | DOI: 10.1097/MCO.0000000000000469

Abstract

Purpose of review

To review recent evidence for the role of dietary carbohydrate in de novo lipogenesis (DNL) and nonalcoholic fatty liver disease (NAFLD).

Recent findings

A large body of evidence suggests that increased hepatic DNL is a significant pathway contributing to the development of NAFLD. Dietary carbohydrates, in particular, fructose, have been shown to stimulate DNL and increase liver fat, although it is debated whether this is due to excess energy or fructose per se. Recent dietary intervention studies conducted in energy balance show that high-fructose diets increase DNL and liver fat, whereas fructose restriction decreases DNL and liver fat.

Summary

The association of high-carbohydrate and high-sugar diets with NAFLD may in part be explained by the effect of sugar on increasing hepatic DNL.